Viridian Therapeutics is a biopharmaceutical company developing medicines for serious and rare diseases, with a focus on thyroid eye disease. It last closed at $30.06 on Nov 17, up 0.87% on the day. The average 12-month price target from 8 analysts is $41.13 (+36.8% from the last close), with a high of $54.00 and a low of $33.00. Analyst consensus is Strong Buy, based on the latest ratings from 8 firms (8 buy, 0 hold, 0 sell). In the past 30 days there were 3 dark pool prints totaling $4.8M, the largest $3.0M.
Each firm's latest rating on VRDN in the past 90 days
Average 12-month target
$41.13
▲ 36.8% upside
Based on 8 analysts who set a price target on VRDN in the past 90 days. The average target is $41.13, with a high of $54.00 and a low of $33.00, compared with the last close of $30.06.
Low $33.00Avg $41.13High $54.00
Blue marker: last close $30.06
Highest target$54.00
Average target$41.13
Lowest target$33.00
Latest rating changes
Wells FargoTarget raised
Nov 10Buy$34 → $39
Leerink PartnersMaintained
Nov 5Buy$54
RBC CapitalTarget raised
Nov 5Buy$38 → $41
Truist SecuritiesTarget raised
Nov 5Buy$39 → $42
Wells FargoTarget raised
Nov 5Buy$31 → $34
Date
Firm
Action
Rating
Price target
Nov 10
Wells Fargo
Target raised
Buy
$34 → $39
Nov 5
Leerink Partners
Maintained
Buy
$54
Nov 5
RBC Capital
Target raised
Buy
$38 → $41
Nov 5
Truist Securities
Target raised
Buy
$39 → $42
Nov 5
Wells Fargo
Target raised
Buy
$31 → $34
Loading…
Technical Analysis
VRDN · as of the Nov 17 close · updated after every close
Uptrend, overbought
The stock is 10% above its 20 day and 23% above its 50 day average. It is 28% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 70), overbought. The nearest support is the Pivot at $29.82, and the nearest resistance the Pivot R1 at $30.36.
Short trendBullish
Long trendBullish
MomentumStrong
StretchOverbought
VolatilityHigh, 4.4%/day
Key levels
$34.2952 week high+14.1%
$31.63Swing high (Nov 11)+5.2%
$30.36Pivot R1+1.0%
$30.06Last close
$29.82Pivot−0.8%
$29.52Pivot S1−1.8%
$26.9720 day average−10.3%
$23.0250 day average−23.4%
$22.10100 day average−26.5%
$21.62Swing low (Aug 14)−28.1%
$21.52200 day average−28.4%
$13.1852 week low−56.2%
Indicators
RSI (14)
70.14
Overbought above 70
Overbought
MACD
2.44
Above its signal line
Bullish
Stochastic
82.5
Near the top of its range
Overbought
ADX (14)
51.6
Strong uptrend
Williams %R
-20.5
Oversold below −80, overbought above −20
Neutral
CCI (20)
67.4
Oversold below −100, overbought above 100
Neutral
Rate of change
+19.5%
Change over 10 sessions
Bullish
ATR (14)
$1.32
Typical daily range, 4.4% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Above
MA 200Above
Rising, nearing overbought
Short trendBullish
Long trendNot enough history
MomentumStrong
StretchNear overbought
VolatilityNormal, 8.9%/day
Key levels
$34.2952 week high+14.1%
$31.63Swing high (Nov 11)+5.2%
$30.36Pivot R1+1.0%
$30.06Last close
$29.82Pivot−0.8%
$29.52Pivot S1−1.8%
$26.9720 day average−10.3%
$23.0250 day average−23.4%
$22.10100 day average−26.5%
$21.62Swing low (Aug 14)−28.1%
$21.52200 day average−28.4%
$13.1852 week low−56.2%
Indicators
RSI (14)
67.19
Strong, overbought above 70
Neutral
MACD
1.79
Above its signal line
Bullish
Stochastic
91.3
Near the top of its range
Overbought
ADX (14)
22.2
Weak trend
Williams %R
-11.2
Oversold below −80, overbought above −20
Overbought
CCI (20)
202.2
Oversold below −100, overbought above 100
Overbought
Rate of change
+41.5%
Change over 10 sessions
Bullish
ATR (14)
$2.68
Typical daily range, 8.9% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Above
MA 200–
What happened before, for VRDN
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how VRDN did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow VRDN usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How VRDN has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2014.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether VRDN is in one of them and how their past VRDN trades turned out.
Viridian Therapeutics is a biopharmaceutical company based in Waltham, Massachusetts. It develops medicines for serious and rare diseases, with its main focus on thyroid eye disease, a rare autoimmune condition that affects the eyes. Its pipeline includes antibody treatments that target the IGF-1R pathway and engineered FcRn inhibitors being studied for several autoimmune disorders. The company is preparing to sell its medicines to patients, physicians and insurers if they are approved.